Pgxl Technologies LLC

Pgxl Technologies LLC is a minority-owned, for-profit limited liability company registered in SAM.gov since 2008, with a focus on developing innovative medical diagnostic technologies. The company appears to specialize in creating advanced diagnostic testing solutions, particularly in the area of non-invasive biomarker-based screening for medical conditions. Their primary research and development efforts seem centered on developing urine-based diagnostic assays that can provide rapid and sensitive testing for complex medical conditions, with a particular emphasis on pediatric and sleep-related disorders.

The company has secured multiple federal grant awards from civilian agencies, including the National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS), and the National Center on Birth Defects and Developmental Disabilities. Their recent grant-funded projects demonstrate a concentrated effort to develop diagnostic technologies for obstructive sleep apnea (OSA), with a specific focus on creating a non-invasive, urine-based screening test for children. These projects involve developing a multiplex immunoassay panel using four specific protein biomarkers, creating innovative urine collection kits, and conducting clinical validation studies. The grants, which range from approximately $200,000 to $301,224, support the company's research towards creating diagnostic tools that can improve screening, diagnosis, and monitoring of complex medical conditions. The company collaborates with research institutions like the University of Louisville Research Foundation and aims to ultimately pursue FDA clearance for their diagnostic technologies.